Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3CNS 3

Conditions

Glioblastoma 100Glioma 42Brain Neoplasms 28Neuroblastoma 25Astrocytoma 18Gliosarcoma 15Sarcoma, Ewing 12Rhabdomyosarcoma 12Neoplasms 12Recurrence 11Medulloblastoma 11Small Cell Lung Carcinoma 8Sarcoma 8Oligodendroglioma 8Melanoma 7Osteosarcoma 6Ependymoma 6Diffuse Intrinsic Pontine Glioma 6Central Nervous System Neoplasms 4Rhabdoid Tumor 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Neuroectodermal Tumors, Primitive 3Neoplasm Metastasis 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Ganglioneuroblastoma 3Desmoplastic Small Round Cell Tumor 3Colorectal Neoplasms 3

Interventions

Rituximab 53Cyclophosphamide 50Lenalidomide 41fludarabine 24obinutuzumab 23Prednisone 19Bendamustine Hydrochloride 19Magnetic Resonance Spectroscopy 18Vincristine 17Doxorubicin 16fludarabine phosphate 15Specimen Handling 15zanubrutinib 13Biopsy 12tazemetostat 10ibrutinib 10Whole-Body Irradiation 10pembrolizumab 9Peripheral Blood Stem Cell Transplantation 9venetoclax 8Mycophenolic Acid 7Etoposide 7axicabtagene ciloleucel 6Radiotherapy 6CT-P10 6Therapeutics 5R-CHOP protocol 5tafasitamab 4polatuzumab vedotin 4acalabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Temozolomide × 1 year × Clear all
NCT05765812 2026-05-28

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Debiopharm International SA

Phase 1/2 Recruiting
116 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT03528642 2026-05-13

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
40 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
408 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡